Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) is a biotechnology company headquartered in San Diego, California, focused on developing and commercializing innovative medicines for central nervous system disorders. The company is a leader in neuropsychiatric drug development, with its flagship product Nuplazid (pimavanserin) approved for Parkinson's disease psychosis["@acadia"].
...
Overview
Mermaid diagram (expand to render)
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) is a biotechnology company headquartered in San Diego, California, focused on developing and commercializing innovative medicines for central nervous system disorders. The company is a leader in neuropsychiatric drug development, with its flagship product Nuplazid (pimavanserin) approved for Parkinson's disease psychosis["@acadia"].
Founded in 1997, Acadia has built expertise in serotonin receptor pharmacology and has expanded into multiple CNS indications including Alzheimer's disease psychosis, schizophrenia, and major depressive disorder["@company2024"].
Pimavanserin (brand name Nuplazid) is a selective serotonin 5-HT2A inverse agonist approved by the FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). It represents the first and only approved treatment specifically for PDP[@nuplazid].
Mechanism of Action:
Selective 5-HT2A receptor inverse agonist
No dopamine receptor activity
Reduces psychotic symptoms without worsening motor function
Improves sleep-wake cycles
Clinical Benefits:
Significant reduction in psychosis scores
No worsening of motor symptoms
Improved caregiver burden
Enhanced quality of life
Approval History:
2016: FDA approval for PDP
2024: Expanded label discussions
ACP-171 (Orexin-2 Receptor Agonist)
ACP-171 is a novel orexin-2 receptor agonist being developed for Parkinson's disease. Orexin-2 receptors play a critical role in wakefulness, and their dysfunction contributes to excessive daytime sleepiness and REM sleep behavior disorder in PD[@orexin2022].
Mechanism:
Selectively activates orexin-2 receptors
Promotes wakefulness
May improve cognitive function
Addresses non-motor symptoms
Development:
Phase 2 clinical trials ongoing
Focus on PD patients with excessive daytime sleepiness
ACP-204
ACP-204 is a next-generation 5-HT2A inverse agonist in Phase 1 development for schizophrenia and potentially other CNS disorders[@acp].
Features:
Enhanced pharmacology
Improved pharmacokinetic properties
Potential for once-daily dosing
Alzheimer's Disease Program
Pimavanserin for ADP
Acadia is developing pimavanserin for Alzheimer's disease psychosis (ADP), a significant unmet need affecting approximately 40-50% of AD patients[@alzheimers2021].
Phase 3 Program (SERENITY):
Enrollment: Patients with AD and psychosis
Design: Randomized, placebo-controlled
Primary endpoint: Change in neuropsychiatric inventory (NPI)
Status: Ongoing
Rationale:
High prevalence of psychosis in AD
No approved treatments
Existing safety data from PDP
Addresses caregiver burden
Research Programs
Neurodegeneration Platform
Acadia is leveraging its CNS expertise to explore new therapeutic approaches: